Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Reducing hair loss during chemotherapy: an interview with Richard Paxman

Reducing hair loss during chemotherapy: an interview with Richard Paxman

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Anthracycline-based breast cancer chemotherapy linked to neurotoxicity

Anthracycline-based breast cancer chemotherapy linked to neurotoxicity

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Arsenic trioxide feasible in low-, high-risk acute promyelocytic leukaemia

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn's Akynzeo for CINV prevention receives EC approval

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients

Janssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to treat STS patients